Basavaraj Balapal

Dr. Basavaraj Balapal

Center for Dementia, Nathan Kline Institute for Psychiatric Research, Orangeburg, South Carolina, USA
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2003 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
BHBasalingappa L. Hungund
Basalingappa L. Hungund
ISIstvan Szakall
Istvan Szakall
AAAgota Adam
Agota Adam
Basavaraj BalapalBasavaraj Balapal
Basavaraj Balapal
CVCsaba Vadasz
Csaba Vadasz
The mechanisms underlying predisposition to alcohol abuse and alcoholism are poorly understood. In this study, we evaluated the role of cannabinoid (CB1) receptors in (i) voluntary alcohol consumption, and (ii) acute alcohol‐induced dopamine (DA) release in the nucleus accumbens, using mice that lack the CB1 receptor gene (CB1–/–). CB1–/– mice exhibited dramatically reduced voluntary alcohol consumption, and completely lacked alcohol‐induced DA release in the nucleus accumbens, as compared to wild‐type mice. The gender difference, with female mice consuming significantly more alcohol than wild‐type male mice, was observed in wild‐type mice, whereas this gender difference was nonexistent in CB1 mutant male and female mice. There was also a significant gender difference, with the wild‐type, heterozygous, and mutant females consuming significantly more liquid and food than wild‐type, heterozygous and mutant males. However, the total volume of fluid consumption and food intake did not differ between wild‐type, heterozygous, and mutant mice. These results strongly suggest that the CB1 receptor system plays an important role in regulating the positive reinforcing properties of alcohol.

27 January 2004 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
BHB L Hungund
B L Hungund
KVK Y Vinod
K Y Vinod
SKS A Kassir
S A Kassir
Basavaraj BalapalBasavaraj Balapal
Basavaraj Balapal
RYR Yalamanchili
R Yalamanchili
VAV Arango
V Arango
Endogenous and exogenous cannabinoids (CBs) acting through the CB1 receptors have been implicated in the regulation of several behavioral and neuroendocrine functions. Modulation of endocannabinoidergic system by ethanol in mouse brain, and the association of suicide and mood disorders with alcoholism suggest possible involvement of the cannabinoidergic system in the pathophysiology of depression and suicide. Therefore, the present study was undertaken to examine the levels of CB1 receptors and mediated signaling in the dorsolateral prefrontal cortex (DLPFC) of subjects with major depression who had died by suicides (depressed suicides, DS). [3H]CP-55,940 and CB1 receptor-stimulated [35S]GTPγS binding sites were analyzed in membranes obtained from DLPFC of DS (10) and matched normal controls (10). Upregulation (24%, P<0.0001) of CB1 receptor density (Bmax) was observed in DS (644.6±48.8 fmol/mg protein) compared with matched controls (493.3±52.7 fmol/mg protein). However, there was no significant alteration in the affinity of receptor (DS; 1.14±0.08 vs control; 1.12±0.10 nM). Higher density of CB1 receptors in DS (38%, P<0.001) was also demonstrated by Western blot analysis. The CB1 receptor-stimulated [35S]GTPγS binding was significantly greater (45%, P<0.001) in the DLPFC of DS compared with matched controls. The observed upregulation of CB1 receptors with concomitant increase in the CB1 receptor-mediated [35S]GTPγS binding suggests a role for enhanced cannabinoidergic signaling in the prefrontal cortex of DS. The cannabinoidergic system may be a novel therapeutic target in the treatment of depression and/or suicidal behavior.

13 June 2017 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
Basavaraj BalapalBasavaraj Balapal
Basavaraj Balapal
MSMadhu Shivakumar
Madhu Shivakumar
VJVikram Joshi
Vikram Joshi
SSShivakumar Subbanna
Shivakumar Subbanna
Most neurodegenerative disorders (NDDs) are characterized by cognitive impairment and other neurological defects. The definite cause of and pathways underlying the progression of theseNDDs are not well‐defined. Several mechanisms have been proposed to contribute to the development ofNDDs. These mechanisms may proceed concurrently or successively, and they differ among cell types at different developmental stages in distinct brain regions. The endocannabinoid system, which involves cannabinoid receptors type 1 (CB1R) and type 2 (CB2R), endogenous cannabinoids and the enzymes that catabolize these compounds, has been shown to contribute to the development ofNDDs in several animal models and human studies. In this review, we discuss the functions of the endocannabinoid system inNDDs and converse the therapeutic efficacy of targeting the endocannabinoid system to rescueNDDs. image

1 March 2007 in Protein & Peptide Letters
Verified
Journal Article
Closed access
PDF file
Basavaraj BalapalBasavaraj Balapal
Basavaraj Balapal
Investigations of the pathways involved in the metabolism of endocannabinoids have grown exponentially in recent years following the discovery of cannabinoid receptors (CB) and their endogenous ligands, such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG). The in vivo biosynthesis of AEA has been shown to occur through several pathways mediated by N-acylphosphatidylethanolamide-phospholipase D (NAPE-PLD), a secretory PLA2 and PLC. 2- AG, a second endocannabinoid is generated through the action of selective enzymes such as phosphatidic acid phsophohydrolase, diacylglycerol lipase (DAGL), phosphoinositide-specific PLC (PI-PLC) and lyso-PLC. A putative membrane transporter or facilitated diffusion is involved in the cellular uptake or release of endocannabinoids. AEA is metabolized by fatty acid amidohydrolase (FAAH) and 2-AG is metabolized by both FAAH and monoacylglycerol lipase (MAGL). The author presents an integrative overview of current research on the enzymes involved in the metabolism of endocannabinoids and discusses possible therapeutic interventions for various diseases, including addiction.

1 February 1999 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
Basavaraj BalapalBasavaraj Balapal
Basavaraj Balapal
BHBasalingappa L Hungund
Basalingappa L Hungund
: In an earlier study, we demonstrated that chronic ethanol (EtOH) exposure down‐regulated the cannabinoid receptors (CB1) in mouse brain synaptic plasma membrane. In the present study, we investigated the effect of chronic EtOH on the formation of anandamide (AnNH), an endogenous cannabimimetic compound, and its precursor N‐arachidonoylphosphatidylethanolamine (N‐ArPE) in SK‐N‐SH cells that were prelabeled with [3H]arachidonic acid. The results indicate that exposure of SK‐N‐SH cells to EtOH (100 mM) for 72 h significantly increased levels of [3H]AnNH and [3H]N‐ArPE (p < 0.05) (1.43‐fold for [3H]AnNH and 1.65‐fold for [3H]N‐ArPE). Exposure of SK‐N‐SH cells to EtOH (100 mM, 24h) inhibited initially the formation of [3H]AnNH at 24 h, followed by a progressive increase, reaching a statistical significance level at 72 h (p < 0.05). [3H]N‐ArPE increased gradually to a statistically significant level after 48 and 72 h (p < 0.05). Incubation with exogenous ethanolamine (7 mM) and EtOH (100 mM, 72 h) did not result in an additive increase in the formation of [3H]AnNH. The formation of [3H]AnNH and [3H]N‐ArPE by EtOH was enhanced by the Ca2+ ionophore A23187 or by the depolarizing agent veratridine and the K+ channel blocker 4‐aminopyridine. Further, the EtOH‐induced formation of [3H]AnNH and [3H]N‐ArPE was inhibited by exogenous AnNH, whereas only [3H]AnNH formation was inhibited by the CB1 receptor antagonist SR141716A and pertussis toxin, suggesting that the CB1 receptor and Gi/o protein mediated the regulation of AnNH levels. The observed increase in the levels of these lipids in SK‐N‐SH cells may be a mechanism for neuronal adaptation and may serve as a compensatory mechanism to counteract the continuous presence of EtOH. The present observation taken together with our previous results indicate the involvement of the endocannabinoid system in mediating some of the pharmacological actions of EtOH and may constitute part of a common brain pathway mediating reinforcement of drugs of abuse including EtOH.

14 April 2015 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
AYA Yuan
A Yuan
HSH Sershen
H Sershen
VEVeeranna
Veeranna
Basavaraj BalapalBasavaraj Balapal
Basavaraj Balapal
AKA Kumar
A Kumar
RNR A Nixon
R A Nixon
Synaptic roles for neurofilament (NF) proteins have rarely been considered. Here, we establish all four NF subunits as integral resident proteins of synapses. Compared with the population in axons, NF subunits isolated from synapses have distinctive stoichiometry and phosphorylation state, and respond differently to perturbations in vivo. Completely eliminating NF proteins from brain by genetically deleting three subunits (α-internexin, NFH and NFL) markedly depresses hippocampal long-term potentiation induction without detectably altering synapse morphology. Deletion of NFM in mice, but not the deletion of any other NF subunit, amplifies dopamine D1-receptor-mediated motor responses to cocaine while redistributing postsynaptic D1-receptors from endosomes to plasma membrane, consistent with a specific modulatory role of NFM in D1-receptor recycling. These results identify a distinct pool of synaptic NF subunits and establish their key role in neurotransmission in vivo, suggesting potential novel influences of NF proteins in psychiatric as well as neurological states.